Table 2.
Clinical outcomes of patients.
| Characteristic | Dexamethasone group (n = 25) |
Control group (n = 25) |
P Value | ||
|---|---|---|---|---|---|
| Survivor (n = 9; 36%) | Non-survivor (n = 16; 64%) | Survivor (n = 10; 40%) | Non-survivor (n = 15; 60%) | ||
| Hospital stay days; median (IQR) | 16 (9-21) | 9.5 (5.5-13) | 8.5 (5-13) | 6 (3-7) | 0.036 |
| ICU stay days; median (IQR) | 7 (4–12) | 7 (4.5–10) | 4.5 (3–5) | 3 (2–3) | <0.001 |
| Noninvasive ventilation; n (%) | 9 (100) | 14 (88) | 10 (100) | 14 (93) | 0.500 |
| Invasive mechanical ventilation; n (%) | 2 (22) | 11 (69) | 1 (10) | 10 (67) | 0.389 |
| SOFA score; median (IQR) | 4 (4–5) | 5 (4–6) | 4 (4–5) | 4 (4–6) | 0.539 |
ICU = intensive care unit; IQR = interquartile range; SOFA=Sequential Organ Failure Assessment.